Bioidentical Hormone Therapy: What the Evidence Actually Says
Bioidentical hormone therapy carried a lot of stigma for years — much of it tracing back to older hormone therapy studies that used different formulations than what's typically prescribed today. That stigma has been shifting, and it's worth understanding what the current, better evidence actually shows.
A Changing Picture
In late 2025, the FDA updated its labeling guidance for menopausal hormone therapy, reflecting a broader re-evaluation of the risk-benefit picture that's been building in the research community for some time. Current evidence shows body-identical hormone therapy — meaning the hormone itself is structurally identical to what your body produces — using regulated pharmaceutical formulations is generally more effective than placebo, and comparably effective to older synthetic hormone therapies, for vasomotor symptoms like hot flashes and night sweats.
An Important Distinction: Regulated vs. Compounded
This is probably the single most important thing to understand before considering this option.
Regulated bioidentical formulations — pharmaceutical-grade patches, gels, and micronized progesterone that have gone through standard drug approval processes — have a solid, well-studied evidence base behind them.
Compounded bioidentical formulations (custom-mixed at a compounding pharmacy, sometimes marketed as more "natural" or personalized) are a different story. Major bodies like ACOG have noted there's meaningfully less high-quality safety and efficacy data for these, along with more variability in dosing consistency from batch to batch. For that reason, compounded formulations generally aren't recommended as a routine first-line choice when standard regulated options exist and are appropriate for many situation.
That said, compounding has its place, and it isn't just a fallback. It's an excellent option when you need a specific formulation that isn't commercially available in a standard, regulated product. A good example: for symptoms that are exclusively vaginal (dryness, irritation, recurrent UTIs, without broader systemic symptoms), estriol is often the ideal choice — it's a weaker estrogen than estradiol, stays much more localized when applied as a vaginal cream, and isn't well absorbed systemically. Since a compounded estriol cream can be formulated at the specific strength and base that suits you, this is a case where compounding isn't a workaround, it's genuinely the more precise tool for the job. This is exactly the kind of decision that should be made together, based on your specific symptoms and goals, rather than assuming "compounded" automatically means either better or worse than a standard option.
The Main Options
Topical estrogen (patches or gels): Generally preferred over oral estrogen, largely because it carries a lower clotting risk — oral estrogen passes through the liver first, which affects clotting factor production in a way transdermal delivery avoids.
Vaginal creams (estradiol or estriol): These aren't interchangeable, and the difference matters. Estradiol is the more potent, primary estrogen your body produces during reproductive years, and is used when broader systemic symptom relief is also a goal. Estriol is a weaker estrogen with much less systemic absorption, and is often preferred specifically for localized vaginal and urinary symptoms (dryness, irritation, recurrent UTIs) when systemic treatment isn't needed or wanted.
Progesterone: Available as micronized oral capsules or transdermal preparations. These have different absorption patterns and different research bases — for instance, oral micronized progesterone has research specifically supporting sleep benefits (related to how it's metabolized), which transdermal forms may not replicate to the same degree.
Frequency and timing of any of these are individualized based on your symptoms, history, and testing. There's no universal starting protocol that fits everyone, which is exactly why this isn't a decision to make from a generic online guide.
Prescribing: Ontario vs. Manitoba
Here's something worth understanding if you're a Manitoba patient: I'm not able to prescribe hormone therapy in Manitoba, but I am able to under my prescribing authority in Ontario.
That doesn't mean this option is off the table if you're in Manitoba — it means the process looks a little different. I'm still an excellent resource for working through the evidence, understanding which formulation and route might make sense for your specific symptoms and history, and preparing you to have a genuinely informed conversation with a prescribing provider. For Manitoba patients, that typically means collaborating directly with your family doctor or a menopause specialist on the actual prescribing piece, while I support the broader picture — testing, monitoring, lifestyle factors, and the nutraceutical and herbal support that often works well alongside hormone therapy.
Safety, Monitoring, and Informed Consent
Whatever route we go, we talk through the pros, cons, cost, and realistic timeline before you decide anything — that's true of every treatment I recommend, not just this one.
Regular retesting is a non-negotiable part of responsible use. The goal is confirming you're staying within safe physiological ranges over time, not assuming a starting dose remains correct indefinitely as your body and needs change. This is especially relevant with therapies where hormone levels can drift higher than intended without monitoring — pellet formulations in particular have documented cases of unpredictable, excessive hormone delivery precisely because dosing can't be adjusted or removed easily once inserted. This is one more reason regulated, actively monitored formulations are generally preferable to unmonitored compounded options, and why ongoing testing (not just a one-time baseline) is part of how I approach this with every patient.
Is This Right for You?
Bioidentical hormone therapy isn't the right choice for everyone, and it's not meant to replace the foundational work — testing, nutraceutical support, lifestyle factors — covered in my main perimenopause and menopause post. For some people, it's an addition to that foundation; for others, the foundational approach is enough on its own. What matters is that the decision is genuinely informed, individualized, and monitored — not chosen (or avoided) based on outdated assumptions.
If hot flashes, sleep disruption, or other symptoms are significantly affecting your quality of life, this is worth a real conversation, regardless of whether you're in Ontario or Manitoba.
Download my Free Perimenopause Guide
This post is educational and general in nature. It isn't a substitute for individualized medical care from a prescribing provider.
References
Makary, M. A., Nguyen, C. P., Høeg, T. B., & Tidmarsh, G. F. (2025). Updated Labeling for Menopausal Hormone Therapy. JAMA.
Akre, K. (2021). Safety and Efficacy of Bioidentical Hormone Therapy in Menopause: A Literature Review.
ACOG Clinical Consensus No. 6 (2023). Compounded Bioidentical Menopausal Hormone Therapy.
Jiang, X., Bossert, A., Parthasarathy, K. N., et al. (2021). Safety assessment of compounded non-FDA-approved hormonal therapy versus FDA-approved hormonal therapy in treating postmenopausal women. Menopause.
Pinkerton, J. V. (2021). Concerns about safety and efficacy of compounded bioidentical hormone therapy. Menopause.